electrical impedance tomography
DeviceElectrical Impedance tomography recording during 5 minutes every day during 7 days
NCT Number: NCT04603755
There are several clinical presentations of SARS-CoV-2 infection. Among the severe forms, pulmonary involvement with respiratory failure is common. Although severe lung involvement with SARS-CoV-2 meets the Berlin criteria for Acute Respiratory Distress Syndrome (ARDS), it differs from classic ARDS in that compliance (reflecting distensibility of the lung parenchyma) is frequently preserved.
If the interest of Electrical Impedance Tomography has been demonstrated in classical ARDS, this is not the case in ARDS with COVID-19.
However, the use of this technique in this particular patient population would make it possible to distinguish patients with severe hypoxemia linked to derecruitment from those without derecruitment, in whom hypoxemia is more likely to be linked to the loss of hypoxic vasoconstriction.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hôpital de la Timone, Marseille, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Electrical Impedance tomography recording during 5 minutes every day during 7 days
Time frame: Up to 7 days
The percentage of derecruitment of dependent areas will be measured every day with Electrical Impedance Tomography.
The response to prone position will be assessed every day.
Direction Centrale du Service de Santé des Armées
Other
Acronym: COVIDEIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04312009
Acute Respiratory Distress Syndrome, COVID-19
Gainesville, Florida, United States
View Trial DetailsNCT04311177
Acute Respiratory Distress Syndrome, COVID-19
Minneapolis, Minnesota, United States
View Trial DetailsNCT04659109
ARDS, Acute Respiratory Distress Syndrome
Strasbourg, France
View Trial DetailsNCT04308668
Acute Respiratory Distress Syndrome, COVID-19
Minneapolis, Minnesota, United States
View Trial Details